ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)

References

• Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE. 2014. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. AAPS J. 16(5):994–1008.
   PubMed Web of Science ®Google Scholar
• Ben-Quan S, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, et al. 2012. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 30(2):184–189.
   PubMed Web of Science ®Google Scholar
• Betts A, Clark T, Jasper P, Tolsma J, van der Graaf PH, Graziani EI, Rosfjord E, Sung M, Ma D, Barletta F. 2020. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1. J Pharmacokinet Pharmacodyn. 47(5):513–526.
   PubMed Web of Science ®Google Scholar
• Bobaly B, Fleury-Souverain S, Beck A, Veuthey JL, Guillarme D, Fekete S. 2018. Current possibilities of liquid chromatography for the characterization of antibody-drug conjugates. J Pharm Biomed Anal. 147:493–505.
   PubMed Web of Science ®Google Scholar
• Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM. 2015. Sacituzumab govitecan (IMMU-132), an anti-trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 26(5):919–931.
   PubMed Web of Science ®Google Scholar
• Chang HP, Li Z, Shah DK. 2022. Physiologically-based pharmacokinetic model for whole-body disposition of MMAE containing antibody-drug conjugate in mice. Pharm Res. 39(1):1–24.
   PubMed Web of Science ®Google Scholar
• Cilliers C, Guo H, Liao J, Christodolu N, Thurber GM. 2016. Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy. AAPS J. 18(5):1117–1130.
   PubMed Web of Science ®Google Scholar
• Cilliers C, Thurber GM. 2018. Standing by for bystander effects: dual-isotope imaging of antibody–drug conjugate and payload distribution. J Nucl Med. 59(9):1459–1460.
   PubMed Web of Science ®Google Scholar
• Davies M, Jones RDO, Grime K, Jansson-Lofmark R, Fretland AJ, Winiwarter S, Morgan P, McGinnity DF. 2020. Improving the accuracy of predicted human pharmacokinetics: lessons learned from the astrazeneca drug pipeline over two decades. Trends Pharmacol Sci. 41(6):390–408.
   PubMed Web of Science ®Google Scholar
• de Mel N, Mulagapati SHR, Cao M, Liu D. 2019. A method to directly analyze free-drug-related species in antibody-drug conjugates without sample preparation. J Chromatogr B Analyt Technol Biomed Life Sci. 1116:51–59.
   PubMed Web of Science ®Google Scholar
• Deeks ED. 2021. Disitamab vedotin: First Approval. Drugs. 81(16):1929–1935.
   PubMed Web of Science ®Google Scholar
• Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, et al. 2017. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 18(11):1512–1522.
   PubMed Web of Science ®Google Scholar
• Dong S, Nessler I, Kopp A, Rubahamya B, Thurber GM. 2022. Predictive simulations in preclinical oncology to guide the translation of biologics. Front Pharmacol. 13:836925.
   PubMed Web of Science ®Google Scholar
• Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL. 2012. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 18(1):248–255.
   PubMed Web of Science ®Google Scholar
• FDA. 2017. FDA approves Mylotarg for treatment of acute myeloid leukemia. [accessed 20 June]. https://www.fda.gov/news-events/press-announcements/fda-approves-mylotarg-treatment-acute-myeloid-leukemia.
   Google Scholar
• FDA. 2020. Drug-drug interaction assessment for therapeutic proteins guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-drug-interaction-assessment-therapeutic-proteins-guidance-industry.
   Google Scholar
• Ferl GZ, Wu AM, DiStefano JJ. III. 2005. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng. 33(11):1640–1652. (2005), 33: 1640–52.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Furuta M, Manabe S, Koga Y, Yasunaga M, Matsumura Y. 2016. Imaging mass spectrometry for the precise design of antibody-drug conjugates. Sci Rep. 6:24954.
   PubMed Web of Science ®Google Scholar
• Garg A, Balthasar JP. 2007. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 34(5):687–709.
   PubMed Web of Science ®Google Scholar
• Gibbs JP. 2010. Prediction of exposure–response relationships to support first-in-human study design. AAPS J. 12(4):750–758.
   PubMed Web of Science ®Google Scholar
• Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris HA, III, LoRusso PM, Yi J-H, Saad O, et al. 2012. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol. 69(5):1229–1240.
   PubMed Web of Science ®Google Scholar
• Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, Purushothama S, Rao C, Shord S, Siguenza P. 2013. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis. 5(9):997–1006.
   PubMed Web of Science ®Google Scholar
• Grafmuller L, Wei C, Ramanathan R, Barletta F, Steenwyk R, Tweed J. 2016. Unconjugated payload quantification and DAR characterization of antibody-drug conjugates using high-resolution MS. Bioanalysis. 8(16):1663–1678.
   PubMed Web of Science ®Google Scholar
• Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber H-P, Sapra P, Barton HA, Betts AM. 2013. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J Pharmacokinet Pharmacodyn. 40(5):557–571.
   PubMed Web of Science ®Google Scholar
• Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou H-R, Upeslacis J, Shochat D, et al. 2002. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 13(1):47–58.
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, et al. 2004. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 10(20):7063–7070.
   PubMed Web of Science ®Google Scholar
• Hinrichs MJM, Ryan PM, Zheng B, Afif-Rider S, Yu XQ, Gunsior M, Zhong H, Harper J, Bezabeh B, Vashisht K, et al. 2017. Fractionated dosing improves preclinical therapeutic index of pyrrolobenzodiazepine-containing antibody drug conjugates. Clin Cancer Res. 23(19):5858–5868.
   PubMed Web of Science ®Google Scholar
• Huang RY, Chen G. 2016. Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends. Drug Discov Today. 21(5):850–855.
   PubMed Web of Science ®Google Scholar
• Huang W, Czuba LC, Isoherranen N. 2020. Mechanistic PBPK modeling of urine pH effect on renal and systemic disposition of methamphetamine and amphetamine. Ournal Pharmacol Exp Ther0. 373:488–501.
   PubMed Web of Science ®Google Scholar
• Huang Y, Mou S, Wang Y, Mu R, Liang M, Rosenbaum AI. 2021. Characterization of antibody-drug conjugate pharmacokinetics and in vivo biotransformation using quantitative intact LC-HRMS and surrogate analyte LC-MRM. Anal Chem. 93(15):6135–6144.
   PubMed Web of Science ®Google Scholar
• Jain N, Smith SW, Ghone S, Tomczuk B. 2015. Current ADC linker chemistry. Pharm Res. 32(11):3526–3540.
   PubMed Web of Science ®Google Scholar
• Jove M, Spencer J, Clench M, Loadman PM, Twelves C. 2019. Precision pharmacology: mass spectrometry imaging and pharmacokinetic drug resistance. Crit Rev Oncol Hematol. 141:153–162.
   PubMed Web of Science ®Google Scholar
• Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, Sliwkowski MX, Fielder PJ, Tibbitts J. 2010. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn. 37(3):221–242.
   PubMed Web of Science ®Google Scholar
• Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguero M. 2013. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis. 5(2):201–226.
   PubMed Web of Science ®Google Scholar
• Khera E, Cilliers C, Bhatnagar S, Thurber GM. 2018. Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy. Mol Syst Des Eng. 3(1):73–88.
   Web of Science ®Google Scholar
• Khera E, Cilliers C, Smith MD, Ganno ML, Lai KC, Keating TA, Kopp A, Nessler I, Abu-Yousif AO, Thurber GM. 2021. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping. Neoplasia. 23(2):210–221.
   PubMed Web of Science ®Google Scholar
• Khera E, Dong S, Huang H, de Bever L, van Delft FL, Thurber GM. 2022. Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates tissue penetration of ADC bystander payloads. Mol Cancer Ther. 21(2):310–321.
   PubMed Web of Science ®Google Scholar
• Khot A, Tibbitts J, Rock D, Shah DK. 2017. Development of a translational physiologically based pharmacokinetic model for antibody-drug conjugates: a case study with T-DM1. AAPS J. 19(6):1715–1734.
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blättler WA, Goldmacher VS. 2006. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66(6):3214–3221.
   PubMed Web of Science ®Google Scholar
• Kraynov E, Kamath AV, Walles M, Tarcsa E, Deslandes A, Iyer RA, Datta-Mannan A, Sriraman P, Bairlein M, Yang JJ, et al. 2016. Current approaches for absorption, distribution, metabolism, and excretion characterization of antibody-drug conjugates: an industry white paper. Drug Metab Dispos. 44(5):617–623.
   PubMed Web of Science ®Google Scholar
• Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, et al. 2010. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 28(16):2698–2704.
   PubMed Web of Science ®Google Scholar
• Li C, Menon R, Walles M, Singh R, Upreti VV, Brackman D, Lee AJ, Endres CJ, Kumar S, Zhang D, et al. 2021. Risk-based pharmacokinetic and drug-drug interaction characterization of antibody-drug conjugates in oncology clinical development: an international consortium for innovation and quality in pharmaceutical development perspective. Clin Pharmacol Ther. 112:754–769.
   PubMed Web of Science ®Google Scholar
• Liao KH, Williams JH, Palani S, Yin D, Meng X. 2022. Joint disposition properties and comprehensive pharmacokinetic characterization of antibody–drug conjugates. AAPS J. 24:73.
   PubMed Web of Science ®Google Scholar
• Liao MZ, Lu D, Kågedal M, Miles D, Samineni D, Liu SN, Li C. 2021. Model-informed therapeutic dose optimization strategies for antibody-drug conjugates in oncology: what can we learn from US food and drug administration-approved antibody-drug conjugates. Clin Pharmacol Ther. 110(5):1216–1230.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev. 23(1–3):3–25.
   Web of Science ®Google Scholar
• Liu Y, Zhou F, Sang H, Ye H, Chen Q, Yao L, Ni P, Wang G, Zhang J. 2017. LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). J Pharm Biomed Anal. 137:170–177.
   PubMed Web of Science ®Google Scholar
• Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD. 2015. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 33(7):733–735.
   PubMed Web of Science ®Google Scholar
• Maurer TS, Smith D, Beaumont K, Di L. 2020. Dose predictions for drug design. J Med Chem. 63(12):6423–6435.
   PubMed Web of Science ®Google Scholar
• Mayer AP, Licea-Perez H, Boram S, Pannullo KE, Kehler J, Evans CA. 2021. Overcoming challenges associated with the bioanalysis of cysteine-conjugated metabolites in the presence of antibody–drug conjugates. Bioanalysis. 13(18):1427–1439.
   Web of Science ®Google Scholar
• Menezes B, Linderman JJ, Thurber GM. 2022. Simulating the selection of resistant cells with bystander killing and antibody coadministration in heterogeneous HER2 oositive tumors. Drug Metab Dispos. 50(1):8–16.
   PubMed Web of Science ®Google Scholar
• Meyer DW, Bou LB, Shum S, Jonas M, Anderson ME, Hamilton JZ, Hunter JH, Wo SW, Wong AO, Okeley NM, et al. 2020. An in vitro assay using cultured kupffer cells can predict the impact of drug conjugation on in vivo antibody pharmacokinetics. Mol Pharm. 17(3):802–809.
   PubMed Web of Science ®Google Scholar
• Mou S, Huang Y, Rosenbaum A. 2018. ADME considerations and bioanalytical strategies for pharmacokinetic assessments of antibody-drug conjugates. Antibodies. 7(4):41.
   Web of Science ®Google Scholar
• Mu R, Yuan J, Huang Y, Meissen JK, Mou S, Liang M, Rosenbaum AI. 2022. Bioanalytical methods and strategic perspectives addressing the rising complexity of novel bioconjugates and delivery routes for biotherapeutics. BioDrugs. 36(2):181–196.
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, et al. 2016. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 22(20):5097–5108.
   PubMed Web of Science ®Google Scholar
• Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. 2014. Site-specific antibody drug conjugates for cancer therapy. MAbs. 6(1):34–45.
   PubMed Web of Science ®Google Scholar
• Park SJ, Lee BI, Park MH, Choi J, Park Y, Park MJ, Lim JH, Lee J, Hwang S, Lee J, et al. 2021. Quantification for antibody-conjugated drug in trastuzumab emtansine and application to in vitro linker stability and in vivo pharmacokinetic study in rat using an immuno-affinity capture liquid chromatography-mass spectrometric method. Appl Sci. 11(20):9437.
   Google Scholar
• Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK, et al. 2013. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 121(24):4854–4860.
   PubMed Web of Science ®Google Scholar
• Poulin P, Jones RDO, Jones HM, Gibson CR, Rowland M, Chien JY, Ring BJ, Adkison KK, Sherry Ku M, He H, et al. 2011. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci. 100(10):4127–4157.
   PubMed Web of Science ®Google Scholar
• Pu J, An B, Vazvaei F, Qu J. 2018. Enrichment of protein therapeutics and biomarkers for LC-MS quantification. Bioanalysis. 10(13):979–982.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. 2007. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 7(9):715–725.
   PubMed Web of Science ®Google Scholar
• Samineni D, Ding H, FM, Shi R, Lu D, Miles D, Mao J, Li C, Jin Jin M, Wright S, Girish Y. Chen 2020. Physiologically based pharmacokinetic model-informed drug development for polatuzumab vedotin: label for drug-drug interactions without dedicated clinical trials. J Clin Pharmacol. 60:S120–S31.
   PubMed Web of Science ®Google Scholar
• Shah DK, Betts AM. 2012. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 39(1):67–86.
   PubMed Web of Science ®Google Scholar
• Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Cyrus Khojasteh S, Tibbitts J, Kaur S, Wang B, Chu YW, et al. 2012. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab. 13(7):901–910.
   PubMed Web of Science ®Google Scholar
• Singh AP, Maass KF, Betts AM, Wittrup KD, Kulkarni C, King LE, Khot A, Shah DK. 2016. Evolution of antibody-drug conjugate tumor disposition model to predict preclinical tumor pharmacokinetics of trastuzumab-emtansine (T-DM1). AAPS J. 18(4):861–875.
   PubMed Web of Science ®Google Scholar
• Singh AP, Seigel GM, Guo L, Verma A, Wong GGL, Cheng HP, Shah DK. 2020. Evolution of the systems pharmacokinetics-pharmacodynamics model for antibody-drug conjugates to characterize tumor heterogeneity and in vivo bystander effect. J Pharmacol Exp Ther. 374(1):184–199.
   PubMed Web of Science ®Google Scholar
• Smith DA, Di L, Kerns EH. 2010. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 9(12):929–939.
   PubMed Web of Science ®Google Scholar
• Stephan JP, Kozak KR, Wong WLT. 2011. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis. 3(6):677–700.
   PubMed Web of Science ®Google Scholar
• Su D, Ng C, Khosraviani M, Yu SF, Cosino E, Kaur S, Xu K. 2016. Custom-designed affinity capture LC-MS F(ab’)2 assay for biotransformation assessment of site-specific antibody drug conjugates. Anal Chem. 88(23):11340–11346.
   PubMed Web of Science ®Google Scholar
• Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, Zhou X, Li S. 2021. Antibody-drug-conjugates: recent advances in linker chemistry. Acta Pharm Sin B. 11(12):3889–3907.
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Yates JWT, Fairman DA. 2022. Free drug theory - no longer just a hypothesis? Pharm Res. 39(2):213–222.
   PubMed Web of Science ®Google Scholar
• Sun X, Ponte JF, Yoder NC, Laleau R, Coccia J, Lanieri L, Qiu Q, Wu R, Hong E, Bogalhas M, et al. 2017. Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates. Bioconjug Chem. 28(5):1371–1381.
   PubMed Web of Science ®Google Scholar
• Suri A, Mould DR, Liu Y, Jang G, Venkatakrishnan K. 2018. Population PK and exposure-response relationships for the antibody-drug conjugate brentuximab vedotin in CTCL patients in the phase III ALCANZA study. Clin Pharmacol Ther. 104(5):989–999.
   PubMed Web of Science ®Google Scholar
• Thurber GM, Wittrup KD. 2008. Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res. 68(9):3334–3341.
   PubMed Web of Science ®Google Scholar
• Thurber GM, Zajic SC, Wittrup KD. 2007. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med. 48(6):995–999.
   PubMed Web of Science ®Google Scholar
• Tong JTW, Paul WRH, Brimble MA, Kavianinia I. 2021. An insight into FDA approved antibody-drug conjugates for cancer therapy. Molecules. 26:5847.
   PubMed Web of Science ®Google Scholar
• Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellstrom I, Hellstrom KE. 1993. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 261(5118):212–215.
   PubMed Web of Science ®Google Scholar
• Vasalou C, Helmlinger G, Gomes B. 2015. A mechanistic tumor penetration model to guide antibody drug conjugate design. PLoS One. 10(3):e0118977/1–e77/20.
   Web of Science ®Google Scholar
• Visser SAG, Aurell M, Jones RDO, Schuck VJA, Egnell A-C, Peters SA, Brynne L, Yates JWT, Jansson-Lofmark R, Tan B, et al. 2013. Model-based drug discovery: implementation and impact. Drug Discov Today. 18(15–16):764–775.
   PubMed Web of Science ®Google Scholar
• Wada R, Erickson HK, Lewis Phillips GD, Provenzano CA, Leipold DD, Mai E, Johnson H, Tibbitts J. 2014. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. Cancer Chemother Pharmacol. 74(5):969–980.
   PubMed Web of Science ®Google Scholar
• Wakankar A, Chen Y, Gokarn Y, Jacobson FS. 2011. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs. 3(2):161–172.
   PubMed Web of Science ®Google Scholar
• Wang H, Rangan VS, Sung MC, Passmore D, Kempe T, Wang X, Thevanayagam L, Pan C, Rao C, Srinivasan M, Zhang Q, et al. 2016. Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans. Biopharm Drug Dispos. 37(2):93–106.
   PubMed Web of Science ®Google Scholar
• Wang J, Song P, Schrieber S, Liu Q, Xu Q, Blumenthal G, Amiri Kordestani L, Cortazar P, Ibrahim A, Justice R, et al. 2014. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clin Pharmacol Ther. 95(5):558–564.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. 2008. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 84(5):548–558.
   PubMed Web of Science ®Google Scholar
• Wei C, Su D, Wang J, Jian W, Zhang D. 2018. LC–MS challenges in characterizing and quantifying monoclonal antibodies (mAb) and Antibody-Drug Conjugates (ADC) in biological samples. Curr Pharmacol Rep. 4(1):45–63.
   Google Scholar
• Wei D, Sullivan M, Espinosa O, Yang L. 2012. A sensitive LC–MS/MS method for the determination of free maytansinoid DM4 concentrations—method development, validation, and application to the nonclinical studies of antitumor agent DM4 conjugated hu-anti-Cripto MAb B3F6 (B3F6-DM4) in rats and monkeys. Int J Mass Spectrom. 312:53–60.
   Web of Science ®Google Scholar
• Xu K, Liu L, Dere R, Mai E, Erickson R, Hendricks A, Lin K, Junutula JR, Kaur S. 2013. Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum. Bioanalysis. 5(9):1057–1071.
   PubMed Web of Science ®Google Scholar
• Xu K, Liu L, Saad OM, Baudys J, Williams L, Leipold D, Shen B, Raab H, Junutula JR, Kim A, et al. 2011. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem. 412(1):56–66.
   PubMed Web of Science ®Google Scholar
• Xu L, Packer LE, Li C, Abdul-Hadi K, Veiby P. 2017. A generic approach for simultaneous measurements of total antibody and cleavable antibody-conjugated drug by LC/MS/MS. Anal Biochem. 537:33–36.
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang Z, Xu S, Xu J, Lin ZJ, Lee DH. 2019. Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry. J Pharm Biomed Anal. 174:441–449.
   PubMed Web of Science ®Google Scholar
• Yin O, Iwata H, Lin C-C, Tamura K, Watanabe J, Wada R, Kastrissios H, AbuTarif M, Garimella T, Lee C, et al. 2021. Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan. Clin Pharmacol Ther. 110(4):986–996.
   PubMed Web of Science ®Google Scholar
• Zhang D, Dragovich PS, Yu SF, Ma Y, Pillow TH, Sadowsky JD, Su D, Wang W, Polson A, Cyrus Khojasteh S, et al. 2019. Exposure-efficacy analysis of antibody-drug conjugates delivering an excessive level of payload to tissues. Drug Metab Dispos. 47(10):1146–1155.
   PubMed Web of Science ®Google Scholar
• Zhu X, Huo S, Xue C, An B, Qu J. 2020. Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates. J Pharm Anal. 10(3):209–220.
   PubMed Web of Science ®Google Scholar